Home Authors Posts by staff

staff

88 POSTS 0 COMMENTS

The role of quantum mechanics in drug discovery

0
Edited by Matteo Iafrate - Pharmaceutical Analytical Chemist

Quantum mechanics allows us to obtain very accurate results in the study of molecules. Over the years, numerous computational methods have been developed that are capable of studying the system under examination with different approaches, always rigorously based on quantum theories. Quantum mechanics attempts to interpret, with excellent results, through statistical probability, the behavior of matter and its energy at the atomic and subatomic level, differentiating itself from classical mechanics, which applies to macroscopic systems. It is important to underline that classical mechanics fails at the molecular level because several properties such as electron delocalization and chemical bonding are strictly linked to quantum effects. Furthermore, quantum mechanical methods offer high accuracy for small systems, while classical methods can handle large systems with reduced accuracy.

Theoretical Foundations

Some of the main theoretical aspects of quantum theory concern wave-particle duality, the quantization of energy, wave function and probability, the superposition principle, the Heisenberg uncertainty principle, and entanglement. The study of time evolution, which describes how the wave function changes over time, with a probabilistic approach, is described by the Schrödinger equation:

Where Ĥ represents the Hamiltonian operator (including kinetic and potential energy terms), and ψ the wave function

In scientific literature, the use of computational methods that make use of quantum mechanics is increasingly present. Among the most widely used are: density functional theory (DFT), Hartree-Fock (HF), quantum mechanics/molecular mechanics (QM/MM), and fragment molecular orbitals (FMO).

Methods and applications

These techniques are based on quantum mechanics, but operate and describe the system under study differently. For example, density functional theory (DFT) is based on the electron density, while the Hartree-Fock method (HF) is based on the wave function. Quantum mechanics/molecular mechanics (QM/MM) is a hybrid method, aiming to combine the accuracy of quantum mechanics  for the molecular regions under study with the efficiency of molecular mechanics (MM). The fragmented molecular orbital method (FMO) splits a large molecule into smaller fragments, with the aim of treating each fragment quantum mechanically and taking into account their interactions.

Many of the results obtained, with the integration of quantum computing, aim to accelerate the drug development cycle and improve workflows, model interactions between small molecules and macromolecules, understand the functioning of enzymes based on electronic effects, model protein-ligand interactions and much more. The increase in computational performance and the excellent results obtained identify the quantum mechanical approach as very promising in drug discovery. In the coming years, computational drug discovery combined with quantum mechanics is expected to become increasingly common.

References

  • Sarfaraz K. Niazi. Quantum Mechanics in Drug Discovery: A Comprehensive Review of Methods, Applications, and Future Directions, Int. J. Mol. Sci., 2025.
  • Yidong Zhou, Jintai Chen, Jinglei Cheng, Xu Cao, Yuanyuan Zhang, Gopal Karemore, Marinka Zitnik, Frederic T. Chong, Junyu Liu, Tianfan Fu, Zhiding Liang. Quantum-machine-assisted drug discovery, npj Drug Discovery, 2026.

Be Ready, the new partnership for pandemic preparedness

0

The new partnership, Be Ready, launched by the European Commission in February 2026, is designed to significantly strengthen and expand research activities dedicated to pandemic preparedness across Europe. Under the initiative, a total budget of €120 million from the Horizon Europe programme will be made available to support projects focusing on emerging and re-emerging pathogens, with the goal of accelerating the development of advanced diagnostics, innovative treatments and next-generation vaccines. The partnership is coordinated by the French research authority ANRS-MIE and brings together a broad network of 81 organisations from 27 countries, reflecting a strong commitment to international collaboration.

Beyond funding, Be Ready will work to align national research priorities among participating countries, fostering greater strategic coherence and reducing fragmentation. It will also enhance coordination in pandemic preparedness research through the definition of a shared strategic and research innovation agenda, enabling a more structured and forward-looking approach.

Joint transnational calls will play a key role in supporting multinational research projects, promoting coordinated funding mechanisms among national and European funders. At the same time, all core components of the initiative will be fully integrated into the wider research ecosystem, ensuring that Be Ready remains active and effective not only during health emergencies but also in the periods between epidemics, strengthening long-term resilience.

Reactions to the EU Court of Justice’s rejection of the annulment of the UWWTD

The European General Court has dismissed EFPIA’s legal action (Case T-158/25) seeking the annulment of the Urban Wastewater Treatment Directive (UWWTD). The ruling, however, is based solely on procedural grounds and does not address the substance of the Directive, leaving the underlying legal questions unresolved.

Court dismisses EFPIA case on procedural grounds

In its decision, the Court concluded that EFPIA had not demonstrated that it was individually concerned by the provisions of the Directive it challenged. This requirement, together with being directly concerned, represents one of the cumulative legal conditions that must be met in order to establish legal standing before the EU General Court. Because these conditions were not considered satisfied, the Court declared the action inadmissible. As a result, the ruling does not examine the merits of EFPIA’s arguments nor the broader legal validity of the Urban Wastewater Treatment Directive.

Following the decision, EFPIA reaffirmed its commitment to ensuring that EU legislation is implemented in full respect of fundamental principles of EU law. Among these, the association highlighted the importance of the “polluter pays” principle, as well as the principles of non-discrimination and proportionality. Since the Court did not address the substance of the case, these legal issues remain open and could still be examined in other proceedings.

Implications for AESGP’s intervention request

The dismissal of EFPIA’s action also resulted in the non-adjudication of AESGP’s request to intervene in the case. AESGP, which represents the self-care industry, had sought to participate in the proceedings to support the arguments raised. According to the association, the key legal questions surrounding proportionality, non-discrimination and the polluter-pays principle should instead be assessed in other ongoing cases, particularly Poland’s legal challenge against the UWWTD (Case C-193/25).

Legal scrutiny of the Directive is continuing through other channels. In parallel with EFPIA’s action, the Irish Pharmaceutical Healthcare Association (IPHA) is advancing a case before the High Court in Ireland, seeking a referral to the Court of Justice of the European Union (CJEU) for a preliminary ruling on the validity of the Directive. The General Court’s order also clarifies an important procedural point: when national courts have doubts about the validity of an EU Directive, they should refer the matter to the CJEU.

For this reason, although EFPIA’s action has been dismissed, the broader legal debate surrounding the Urban Wastewater Treatment Directive is likely to continue in both national courts and EU-level proceedings.

Concept paper on the revision of Annex 15

0

As agreed during the 115th meeting of EMA’s GMP/GDP Inspectors Working Group (GMDP IWG) in September 2024, the European Medicines Agency has launched a targeted revision of Annex 15 of the Good Manufacturing Practices (GMPs). The consultation period on the Concept Paper, jointly published by EMA and PIC/S in February 2026, will remain open until 9 April 2026. This initial phase will be followed by the publication of a revised draft guideline and a second round of consultation, with the final text expected to be published by the end of 2026.

The initiative to revise Annex 15 stems from lessons learned since 2020 regarding the presence of N-nitrosamine impurities in medicines containing sartans as active ingredients. The report published on the case highlighted, among other aspects, an insufficient level of knowledge and understanding of the manufacturing processes of active substances by their producers. This lack of process understanding contributed to quality issues affecting active pharmaceutical ingredients (APIs) and to inadequate measures to control contamination by impurities. The report on the nitrosamine case ultimately recommended making the application of Annex 15 mandatory also for API manufacturers.

This recommendation was taken up in 2024 during the 115th meeting of the GMDP IWG and has now led to the publication of the new Concept Paper by EMA and PIC/S, the international scheme for cooperation in pharmaceutical inspections.

Objectives of the revision

According to the document, the revision aims to extend the scope of Annex 15 to manufacturers of active substances, both chemical and biological. The update will also introduce selected modifications to the current text and strengthen the link with the provisions set out in Part II of the EU GMP guidelines, which specifically address active substances. Another key objective is to align the Annex more closely with the ICH Q9 (R1) guideline on Quality Risk Management, in order to ensure greater consistency between the two frameworks when making decisions related to qualification and validation activities.

The Concept Paper indicates that greater emphasis should be placed on the validation documentation for active substances, including the Validation Master File, as well as on the definition of a clearer qualification and validation policy. Such a policy should specify roles and responsibilities, the criteria used, including acceptance criteria, and the monitoring strategies adopted during the lifecycle of the manufacturing process.

A lifecycle-based approach to validation

At the core of the proposed revision is the introduction of a lifecycle-based approach to validation. This approach would cover the entire process lifecycle, from process design and qualification to ongoing performance monitoring and final evaluation, based on data and metrics collected throughout the manufacturing lifecycle.

The Concept Paper also highlights the need for robust procedures to investigate non-conforming results, supported by appropriate corrective and preventive actions (CAPA). In the area of qualification, the revision is expected to strengthen several key concepts, including the definition of User Requirements Specifications (URS) and the role of Factory Acceptance Testing and Site Acceptance Testing (FAT/SAT).

EMA committees’ 2026 work plans: regulatory priorities and strategic focus

The European Medicines Agency (EMA) has outlined its 2026 priorities through the annual work plans of its scientific committees, marking a year that will be crucial for regulatory transition and innovation. A central element will be the preparation for the implementation of the new EU pharmaceutical legislation. The Committee for Medicinal Products for Human Use (CHMP) will focus on pre-authorisation activities, initial evaluations, specialised scientific areas and horizontal initiatives, ensuring readiness for the evolving legal framework.

Orphan medicinal products and pharmacovigilance

The Committee for Orphan Medicinal Products (COMP) will continue its evidence-based assessment of orphan designations and maintenance of orphan status. Planned activities also include work on indirect comparisons and the integration of new approach methodologies (NAMs), reinforcing scientific robustness in regulatory decision-making.

Pharmacovigilance will remain high on the agenda. The Pharmacovigilance Risk Assessment Committee (PRAC) will revise Good Vigilance Practices (GVPs) and other guidance documents. Support will also be provided for the use of artificial intelligence and real-world evidence in regulatory pharmacovigilance activities, reflecting the growing role of data-driven approaches in safety monitoring.

The paediatric drugs

The Paediatric Committee (PDCO) will prioritise making paediatric investigation plans (PIPs) more feasible and ensuring the timely completion of development programmes. Activities will include developing therapeutic area strategies and strengthening cooperation with the Clinical Trials Coordination Group (CTCG). The PDCO will also explore innovative ways to generate and use data for marketing authorisation, including the implementation of the ICH E11 guideline on paediatric extrapolation.

Overall, the EMA work plans for 2026 underline a year shaped by regulatory preparedness, methodological evolution and the progressive integration of digital tools into medicines regulation across the European Union.

EMA-FDA joint principles for the use of AI along medicines lifecycle

0

The European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have jointly published a document outlining ten principles for the responsible use of artificial intelligence (AI) throughout the medicines lifecycle. The initiative marks a coordinated effort between the two regulators to support the future development of AI guidance across different jurisdictions. The joint principles will provide a common reference framework for the development, validation and oversight of AI systems used in activities related to medicinal products, from early research to post-market phases.

A human-centric system

According to the document, AI systems should be human-centric by design and developed using a risk-based approach. This approach must include appropriate validation processes and risk mitigation measures proportionate to the intended use and potential impact of the system. The development and deployment of AI should comply with applicable legal, ethical, technical, scientific and cybersecurity standards, as well as relevant regulatory requirements, including Good Practices (GxP). A clearly defined context of use is another key requirement. Each AI system should be designed and implemented for a specific purpose, with its scope and limitations clearly documented. Development should involve multidisciplinary expertise across the entire lifecycle of the system, reflecting the complexity of the pharmaceutical regulatory environment. In line with GxP principles, detailed documentation is expected. This includes data source provenance, data processing steps and analytical decisions taken during model development and operation.

Governance and risk-based AI oversight

Robust governance mechanisms must also be in place to ensure the protection of privacy and sensitive information. Data used in AI systems should be fit-for-use, ensuring adequate interpretability, explainability and predictive performance. The agencies stress that performance assessments should follow a risk-based approach and evaluate the AI system as a whole, including human-AI interactions where relevant.The document also calls for the implementation of a risk-based quality management system throughout the technology’s lifecycle. This is aimed at ensuring continuous oversight, reliability and compliance over time. Finally, information generated by AI systems should be presented to users in plain language, ensuring clarity, accessibility and contextual relevance. With these joint principles, EMA and FDA signal a shared commitment to promoting consistent and responsible use of AI in the medicines regulatory space, laying the groundwork for future guidance in this rapidly evolving field.

QIG workplan 2026-2028: AI, digitalisation and advanced manufacturing

0

The 2026–2028 Workplan of the European Medicines Agency’s Quality Innovation Group (QIG) outlines a strategic roadmap that is set to shape the future of pharmaceutical manufacturing, quality control, and regulatory science across Europe. The plan confirms the growing importance of innovation-driven approaches in the production and oversight of medicines: particularly, as the sector accelerates its adoption of artificial intelligence, digital technologies, and next-generation manufacturing models.

In the short term, the QIG will focus on how best to support innovation in the manufacture and control of medicinal products. Key areas under consideration include pharmaceutical process models, the application of artificial intelligence in quality and production environments, and the broader digitalisation of manufacturing and regulatory workflows. Emerging technologies such as 3D printing, platform-based production systems, personalised medicines, continuous manufacturing, and decentralised manufacturing are also expected to play a central role in the group’s activities.

The importance of collaboration

A major objective of the Workplan is the continued strengthening of the EU regulatory network. In this context, the QIG will provide support across all quality and Good Manufacturing Practice (GMP) aspects related to advanced manufacturing technologies. Ensuring that innovative production methods can be implemented safely, consistently, and in compliance with EU standards remains a critical priority, particularly as automation and digital transformation reshape pharmaceutical supply chains.

The Workplan also highlights the importance of stakeholder engagement and international collaboration. This reflects the increasingly global nature of pharmaceutical innovation, where regulatory convergence and shared best practices are essential for enabling the responsible deployment of new manufacturing approaches across regions. Looking further ahead, the long-term strategic goals of the Quality Innovation Group prioritise transformative technologies such as 3D bioprinting, artificial intelligence, automation and robotics, as well as novel regulatory concepts aligned with evolving pharmaceutical legislation. Topics such as decentralised manufacturing models, platform technologies, bioinformatics, next-generation sequencing, and enhanced traceability systems for personalised medicines are expected to become increasingly relevant in the coming years.

From regulation to innovation

From a regulatory science perspective, planned actions will focus on strengthening research and quality innovation within the EU network, while improving the scientific and regulatory capacity, resilience, and overall capability of European authorities. The QIG will also support the implementation of the new pharmaceutical legislation, working in close collaboration with other EMA Committees and Working Parties. Overall, the EMA Quality Innovation Group Workplan for 2026–2028 positions innovation, digitalisation, and AI-driven manufacturing as central pillars of the European pharmaceutical landscape. Its priorities will have direct implications not only for pharmaceutical companies, but also for IT professionals, automation experts, and stakeholders involved in the digital transformation of life sciences manufacturing.

EU-India FTA: new opportunities for innovation, healthcare and research collaboration

0

On 27 January 2026, the 16th EU-India Summit was held in New Delhi, marking a significant milestone with the signing of the new EU-India Free Trade Agreement (FTA). The agreement aims to strengthen strategic cooperation between the European Union and India, with a strong focus on innovation, research and advanced technologies. One of the key pillars of the EU-India FTA is the promotion of collaborative research in high-impact sectors such as biotechnology, artificial intelligence (AI), quantum technologies, clean technologies and advanced semiconductors. These areas are considered critical for long-term economic growth, technological sovereignty and global competitiveness on both sides.

The agreement places particular emphasis on healthcare and research ecosystems. As part of the new framework, EU-India Innovation Hubs will be established to facilitate structured dialogue, knowledge exchange and the development of joint research and innovation projects in emerging technologies. These hubs are expected to act as platforms connecting public institutions, industry stakeholders, research organisations and start-ups. In parallel, the European Union and India plan to launch an EU-India Startup Partnership, in cooperation with the European Innovation Council, Start-up India and EU Member States. The initiative aims to foster cross-border collaboration, support start-up scaling and encourage investment flows between the two innovation ecosystems. The potential association of India to Horizon Europe, the EU’s flagship research and innovation programme, is also under consideration, further reinforcing scientific cooperation.

Beyond innovation and research, the agreement outlines future collaboration in regulatory cooperation and health security capacity building. The EU and India have committed to working together to strengthen a resilient global health architecture, with a focus on core mandates, efficiency and the avoidance of duplication. This approach reflects shared priorities in preparedness, resilience and coordinated responses to global health challenges.

Japan shall join Horizon Europe in 2026

0

The year 2025 came to a close with the formal announcement that the European Commission and the Japanese government had successfully concluded negotiations on Japan’s association with Horizon Europe, the European Union’s flagship research and innovation framework programme. While the negotiations are now complete, the final agreement is expected to be officially signed in 2026, marking a new phase in EU–Japan scientific cooperation.

Once the association enters into force, Japanese researchers and research organisations will be able to participate in Horizon Europe on an equal footing with entities from EU Member States and other associated countries. This includes the possibility to lead and coordinate their own research and innovation projects, submit proposals directly to the programme, and apply for and receive EU funding. The agreement is also expected to facilitate closer and more structured collaboration between Japanese institutions and partners based in the EU and in other countries associated with Horizon Europe. To ensure continuity and avoid delays in participation, transitional arrangements have been put in place. These will allow Japanese entities to apply to Horizon Europe calls starting from 2026 onwards, with their status treated as that of “eligible entities” from an associated country, even before the formal signature of the agreement.

According to the European Commission, Japan’s association will be primarily focused on Pillar II of Horizon Europe. This pillar addresses major societal challenges through large-scale, multinational collaborative projects, covering strategic areas such as digital technologies, climate, energy, health, and industrial competitiveness. Japan’s entry into the programme aligns with a broader strategy to strengthen international cooperation in research and innovation with leading global partners. Japan thus joins a growing group of major scientific and technological powerhouses already associated with Horizon Europe, including South Korea, Switzerland, Egypt, Canada, the United Kingdom and New Zealand.

EFPIA’s report on AI across the medicines lifecycle

0

Artificial intelligence (AI) is increasingly reshaping the pharmaceutical industry, moving beyond experimental use cases to become a concrete component of regulatory decision-making and patient-facing processes. Its growing adoption is redefining how medicinal products are researched, developed, approved and monitored throughout their lifecycle. A recent report published by EFPIA explores in detail how robust AI governance frameworks can be effectively embedded both in medicinal product research and development (R&D) and in post-authorisation activities. The document highlights the need for a structured and harmonised approach to AI adoption, capable of balancing innovation with regulatory compliance and patient safety.

Central to the report is the concept of trust. EFPIA underlines that trust in AI systems can only be achieved through transparency, accountability and continuous dialogue between pharmaceutical companies and regulatory authorities. Rather than treating AI as a purely technical enabler, the report frames it as a socio-technical system whose impact extends to organisational processes, regulatory interactions and clinical outcomes. Across the case studies analysed, several recurring best practices emerge. Data quality and standardisation are identified as foundational elements: without consistent, well-governed datasets, AI models risk producing unreliable outputs that cannot be confidently used in regulated environments. Equally important is investment in training and change management, which plays a critical role in fostering acceptance of AI tools among both technical teams and regulatory stakeholders.

The report also stresses the importance of early AI integration and governance. Embedding governance mechanisms from the initial design phases helps align AI-driven innovation with regulatory expectations, reducing friction at later stages. In this context, model transparency and explainability are prioritised over raw predictive performance, reflecting regulators’ need to understand how and why an algorithm reaches a given conclusion. Finally, EFPIA points to the need for proactive monitoring and continuous risk assessment throughout the AI lifecycle. Even during pilot projects or exploratory phases, potential risks must be identified and managed early, ensuring that AI solutions remain compliant, robust and fit for purpose as they scale. This approach, the report concludes, is essential for enabling the sustainable and responsible use of AI across the pharmaceutical ecosystem.

Newsstand

  • Supplement to n.5 - October 2025 NCF International n.2 - 2025
  • NCF International n.1 - 2025
  • Supplemento to n.9 - October 2024 NCF International n.3 - 2024